Financials in USD. Standardized financial statements.
A compact view of how Blueprint Medicines Corporation turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $508.82M | $249.38M | $204.04M | $180.08M | $793.74M | $66.51M | $44.52M | $21.43M | $27.77M | $11.40M |
| Revenue Growth? | +104.0% | +22.2% | +13.3% | -77.3% | +1093.4% | +49.4% | +107.8% | -22.9% | +143.6% | 0.0% |
| Cost of Revenue? | $20.16M | $12.80M | $17.81M | $17.93M | $425,000 | $0 | $243.62M | $144.69M | $81.13M | $48.59M |
| Gross Profit? | $488.66M | $236.58M | $186.22M | $162.15M | $793.31M | $66.51M | -$199.10M | -$123.26M | -$53.36M | -$37.19M |
| Gross Margin? | +96.0% | +94.9% | +91.3% | +90.0% | +99.9% | +100.0% | -447.2% | -575.3% | -192.1% | -326.2% |
| Operating Expenses? | $700.71M | $722.86M | $723.74M | $804.13M | $484.60M | $427.84M | $291.55M | $172.67M | $100.35M | $63.04M |
| Operating Income? | -$212.04M | -$486.28M | -$549.25M | -$648.46M | $302.15M | -$366.58M | -$247.03M | -$149.48M | -$73.61M | -$53.02M |
| EBITDA? | $19.23M | -$470.36M | -$515.41M | -$628.30M | $308.71M | -$356.07M | -$242.78M | -$149.67M | -$70.44M | -$51.13M |
| Income Before Tax | -$65.86M | -$506.02M | -$552.28M | -$641.08M | $314.94M | -$347.69M | -$236.64M | -$148.12M | -$72.50M | -$52.77M |
| Income Tax Expense | $1.23M | $968,000 | $5.24M | $3.00M | $1.06M | $0 | $0 | $1.99M | -$562,000 | -$681,000 |
| Net Income? | -$67.09M | -$506.98M | -$557.52M | -$644.09M | $313.88M | -$328.70M | -$236.64M | -$148.12M | -$72.50M | -$52.77M |
| EPS? | $-1.07 | $-8.37 | $-9.35 | $-11.01 | $5.76 | $-6.87 | $-5.39 | $-3.92 | $-2.64 | $-2.89 |
| Diluted EPS? | $-1.07 | $-8.37 | $-9.35 | $-11.01 | $5.59 | $-6.87 | $-5.39 | $-3.92 | $-2.64 | $-2.89 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality